ArticleTranslational lung cancer research2025
Patient-reported outcomes of radiofrequency ablation-video-assisted thoracoscopic surgery (VATS) hybrid surgery
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Perioperative fatigue after lung resection for pulmonary nodules and early-stage lung cancer: a systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- Application of percutaneous cryoablation for pulmonary nodules and influence in pulmonary function.BMC cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Computed tomography-guided radiofrequency ablation combined with video-assisted thoracoscopic surgery (VATS) hybrid surgery (HBD) treats multiple primary lung nodules by simultaneously ablating satellite nodules and resecting the primary lesion. However, its postoperative patient-centered recovery trajectories remain unclear compared to standard VATS. This study aims to illustrate the patient-reported outcomes (PROs) of HBD and VATS, and to investigate whether a hybrid approach can serve as a safe and effective alternative for cases traditionally deemed challenging, thereby potentially expanding the indications for minimally invasive therapy. Methods: A longitudinal cohort study included 183 patients with a primary clinical stage 0/IA non-small cell lung cancer (NSCLC) and at least one additional ipsilateral nodule (118 VATS, 65 HBD) treated at a national cancer center was conducted (April 2024-December 2024). PROs were assessed using the MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) preoperatively and at 17 timepoints postoperatively (days 1-90). Moderate-to-severe symptoms/functional impairment was defined as scores ≥4/10. Mixed-effects models and Kaplan-Meier analyses evaluated recovery trajectories. Results: A total of 183 patients with stage 0/IA NSCLC (118 VATS, 65 HBD) treated at a national cancer center were selected. Both groups showed similar baseline characteristics except sex distribution (HBD: 83.1% female Conclusions: HBD achieves comparable PRO-based recovery to VATS while preserving lung parenchyma, though with distinct symptom trade-offs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.